Multidimensional Family Therapy, an Introduction (Part 1 of 2)
Multidimensional Family Therapy, An Introduction (Part 1 of 2) – An overview of the Multidimensional Family Therapy model, presented by its creator, Howard Liddle. This is part 1 of 2. To see additional videos, including part two of this MDFT overview, please go to our YouTube channel (www.youtube.com ), or go directly to the videos using the following links: (1) Multidimensional Family Therapy, An Introduction (Part 1 of 2) www.youtube.com (2) Multidimensional Family Therapy, An Introduction (Part 2 of 2) www.youtube.com (3) Risk and Protective Factors www.youtube.com (4) MDFT – Juvenile Justice www.youtube.com (5) Adolescent Treatment www.youtube.com (6) Adolescent Drug Abuse MDFT Case Study (Part 1 of 2) www.youtube.com (7) Adolescent Drug Abuse MDFT Case Study (Part 2 of 2) www.youtube.com (8) Future of Adolescent Treatment and Research www.youtube.com (9) Dr. Howard Liddle, Multidimensional Family Therapy DVD (APA Video Series) www.youtube.com (10) MDFT (Multidimensional Family Therapy, in Dutch with English subtitles) www.youtube.com (11) MDFT (Multidimensional Family Therapy, Dutch version) www.youtube.com (12) MDFT (Multidimensional Family Therapy, German version) www.youtube.com About Dr. Howard Liddle: Howard A. Liddle, EdD, ABPP (Family Psychology), is Professor, in the Departments of Epidemiology and Public Health and Psychology, and Director, of the Center for Treatment Research on Adolescent Drug Abuse at the University of Miami Miller School of Medicine (www.miami.edu\ctrada).Trained as a psychologist and family …
Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
Filed under: drug abuse treatment outcome study
A Phase II randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD was initiated in September 2012. About Ohr Pharmaceutical Inc. Ohr Pharmaceutical Inc. (OTCBB: OHRP …
Read more on Sacramento Bee
The Zacks Analyst Blog Highlights: McGraw-Hill, Moody's, Gilead Sciences …
Filed under: drug abuse treatment outcome study
One negative outcome of all this uncertainty is that U.S. companies, despite rock-bottom interest rates, have hoarded about $ 1.7 trillion in cash. Judging from the … Data from study 102 revealed that Stribild was non-inferior to Gilead's Atripla …
Read more on Sacramento Bee
AARP Opposes Cost-Shifting to Seniors in Medicare and Medicaid
Filed under: drug abuse treatment outcome study
Towards that end, we have worked with both sides of the aisle to support key pieces of legislation, such as the Balanced Budget Act of 1997, the Medicare Drug Improvement and Modernization Act, and most recently, the Affordable Care Act. … commitment …
Read more on eNews Park Forest